Short Bowel Syndrome (SBS) - Global Strategic Business Report

The global market for Short Bowel Syndrome (SBS) was estimated at US$1.7 Billion in 2025 and is projected to reach US$2.2 Billion by 2032, growing at a CAGR of 4.0% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Short Bowel Syndrome (SBS) Market - Key Trends and Drivers Summarized

Why Is the Short Bowel Syndrome (SBS) Market Gaining Attention in the Healthcare Industry?

The Short Bowel Syndrome (SBS) market is gaining attention in the healthcare industry due to the rising incidence of gastrointestinal disorders and the increasing need for effective management of SBS, a condition characterized by inadequate nutrient absorption due to surgical removal of a significant portion of the small intestine. Patients with SBS face challenges such as malnutrition, dehydration, diarrhea, and dependence on parenteral nutrition (PN) or enteral nutrition (EN) support, making comprehensive management essential. The growing focus on improving patient outcomes, quality of life, and reducing long-term healthcare costs is driving the demand for innovative therapies, including pharmacological treatments, nutritional support, and surgical interventions, in the management of SBS.

How Are Technological Advancements and New Therapies Transforming the SBS Market?

Technological advancements and new therapies are significantly transforming the SBS market by enhancing the efficacy, safety, and convenience of SBS management. The development of novel pharmacological treatments, such as glucagon-like peptide-2 (GLP-2) agonists, growth hormones, and enzyme replacements, is improving intestinal adaptation, absorption, and fluid retention, reducing the need for parenteral nutrition and hospital visits. The emergence of personalized, multidisciplinary, and nutrition-based care models, supported by telemedicine, remote monitoring, and digital health platforms, is enabling more tailored and patient-centric approaches to SBS management. Additionally, advancements in regenerative medicine, gene therapy, and microbiome-based treatments are opening new frontiers in SBS research, offering the potential for long-term solutions and reduced complications.

Which Market Segments Are Leading the Adoption of SBS Therapies?

Treatment types include parenteral nutrition (PN), enteral nutrition (EN), pharmacological therapies, and surgical interventions, with PN and pharmacological therapies being the most widely adopted due to their critical role in providing essential nutrients, fluids, and managing symptoms. Patient types encompass pediatric, adult, and post-surgical SBS patients, with pediatric and post-surgical segments leading the market due to the high prevalence of congenital, post-surgical, and acquired SBS conditions. Distribution channels include hospitals, specialty clinics, retail pharmacies, and home healthcare, with hospitals and specialty clinics being the largest segments due to the need for specialized care, monitoring, and support. Asia-Pacific is emerging as a high-growth region driven by improving healthcare infrastructure and rising incidence of gastrointestinal disorders.

What Are the Key Drivers of Growth in the Short Bowel Syndrome (SBS) Market?

The growth in the Short Bowel Syndrome (SBS) market is driven by several factors, including the rising incidence of SBS and other gastrointestinal disorders, technological advancements in parenteral nutrition, enzymes, and pharmacological treatments, and the increasing use of human growth hormone, glucagon-like peptide-2 (GLP-2) agonists, and dietary supplements in SBS management. The development of orphan drugs, biologics, and novel surgical techniques with enhanced efficacy, safety, and convenience is driving market adoption among hospitals, specialty clinics, and home healthcare providers. The focus on enhancing multidisciplinary, patient-centric care models, self-management, and remote monitoring is expanding the market reach among pediatric, adult, and post-surgical patients. The growing use of SBS therapies in combination with regenerative medicine, digital health, and artificial intelligence, coupled with the demand for personalized and nutrition-based SBS care solutions, is creating new opportunities for market growth. Additionally, the increasing investments in R&D for gene therapy, stem cell therapy, and microbiome-based treatments are further supporting market expansion.

Report Scope

The report analyzes the Short Bowel Syndrome (SBS) market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Type (GLP-2 Type, Growth Hormone Type, Glutamine Type); Distribution Channel (Hospital Pharmacies Distribution Channel, Online & Retail Pharmacies Distribution Channel)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the GLP-2 Type segment, which is expected to reach US$889.1 Million by 2032 with a CAGR of a 3.0%. The Growth Hormone Type segment is also set to grow at 4.3% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $489.2 Million in 2025, and China, forecasted to grow at an impressive 4.1% CAGR to reach $397.0 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Short Bowel Syndrome (SBS) Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Short Bowel Syndrome (SBS) Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Short Bowel Syndrome (SBS) Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Ardelyx, Inc., Emmaus Life Sciences, Inc., Merck KgaA, Naia Pharmaceuticals Inc., Nutrien Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Short Bowel Syndrome (SBS) market report include:

• Ardelyx, Inc.
• Emmaus Life Sciences, Inc.
• Merck KgaA
• Naia Pharmaceuticals Inc.
• Nutrien Ltd.
• OxThera AB
• Shire PLC
• Zealand Pharma A/S

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 33 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.